Stock Events

Stock Events

Hemostemix 

€0.04
6
+€0+0% Thursday 06:43

Statistics

Day High
0.04
Day Low
0.04
52W High
0.06
52W Low
0.03
Volume
-
Avg. Volume
-
Mkt Cap
7.35M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-3.52MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2VF0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is involved in the development of drugs and therapies, including those in the regenerative medicine space, competing with Hemostemix's stem cell therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis focuses on innovative medicines and directly competes in the regenerative medicine sector, offering alternatives to Hemostemix's solutions.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a biopharmaceutical company that develops treatments for various conditions, including those that could compete with stem cell therapies offered by Hemostemix.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and has interests in developing treatments that could compete with Hemostemix's stem cell-based therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating new therapies, including those in the regenerative medicine area, potentially competing with Hemostemix.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic therapies, including gene editing, a field that competes with stem cell therapy approaches like those of Hemostemix.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a revolutionary approach that competes with traditional stem cell therapies offered by Hemostemix.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine is involved in gene editing, directly competing with the stem cell therapy market that Hemostemix is part of.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the gene editing space, offering competitive alternatives to stem cell-based therapies like those developed by Hemostemix.

About

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Thomas A. Smeenk B.A., BA Hons
Country
CA
ISIN
CA4236943060
WKN
000A2QQGU

Listings

OTC Link
US
HMTXF
V
CA
HEM.V
F
DE
2VF0.F

0 Comments

Share your thoughts

FAQ

What is Hemostemix stock price today?▼
The current price of 2VF0.F is €0.04 EUR — it has increased by +0% in the past 24 hours. Watch Hemostemix stock price performance more closely on the chart.
What is Hemostemix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hemostemix stocks are traded under the ticker 2VF0.F.
Is Hemostemix stock price growing?▼
2VF0.F stock has fallen by -1.23% compared to the previous week, the month change is a +0% rise, over the last year Hemostemix has showed a +2.56% increase.
What is Hemostemix market cap?▼
Today Hemostemix has the market capitalization of 7.35M
When is the next Hemostemix earnings date?▼
Hemostemix is going to release the next earnings report on May 05, 2026.
What is Hemostemix revenue for the last year?▼
Hemostemix revenue for the last year amounts to 0 EUR.
What is Hemostemix net income for the last year?▼
2VF0.F net income for the last year is -3.52M EUR.
In which sector is Hemostemix located?▼
Hemostemix operates in the Health Care sector.
When did Hemostemix complete a stock split?▼
Hemostemix has not had any recent stock splits.
Where is Hemostemix headquartered?▼
Hemostemix is headquartered in Calgary, CA.